inhibition hepatitis b virus replication drug-induced depletion nucleocapsids 
chronic hepatitis b virus hbv infection major cause liver disease interferon-alpha nucleosidic inhibitors viral polymerase 3tc adefovir approved therapy however therapies limited side effects interferon substantial resistance virus nucleosidic inhibitors potent new antiviral compounds suitable monotherapy combination therapy highly desired describe non-nucleosidic inhibitors hbv nucleocapsid maturation possess vitro vivo antiviral activity inhibitors potential future therapeutic regimens combat chronic hbv infection 
